Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis...
Saved in:
Main Authors: | Matteo Megna, Cataldo Patruno, Maria Rita Bongiorno, Alessio Gambardella, Claudio Guarneri, Caterina Foti, Serena Lembo, Francesco Loconsole, Gabriella Fabbrocini |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-07-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2022.2062280 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
by: Federico Pirro, et al.
Published: (2025-01-01) -
Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
by: Ece Erbağcı, et al.
Published: (2025-01-01) -
Recurrent NTM pulmonary disease despite avoidance of hot spring exposure in a plaque psoriasis patient treated with Secukinumab: a case report
by: Yixiao Wei, et al.
Published: (2025-01-01) -
Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review
by: Eleonora Celletti, et al.
Published: (2025-01-01) -
Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease
by: Ronghui Li, et al.
Published: (2025-01-01)